Huesanteng commits 1 billion yuan investment in Bloomage BioBeauty
According to Huxiu, Jinbo Biotech announced a revised private placement plan on September 28, reducing the maximum shares issued from 7.1757 million to 3.6072 million and cutting the total fundraising from up to 2 billion yuan to 1 billion yuan, while canceling an 850 million yuan supplementary liquidity project. On September 29, Jinbo Biotech’s stock closed up 0.81% at 128.66 yuan, with intraday volatility of 8.7%. Yangshengtang pledged to begin secondary-market purchases within 12 months and complete at least 1 billion yuan in buys within 18 months, with a non-transferable plan and a rare donation if the 18-month target is not met, irrevocably earmarked for FAST database and product development platform projects.
Key facts
- 01Jinbo Biotech announced a revised private placement plan on Sep 28, reducing the maximum new shares to 3.6072 million and fundraising to 1 billion yuan.
- 02The original 2 billion yuan fundraising and 717.57 million shares cap were adjusted downward; the 85 billion yuan liquidity project was canceled.
- 03Jinbo Biotech’s stock closed up 0.81% on Sep 29, at 128.66 yuan, with intraday volatility of 8.7%.
- 04Yangshengtang pledged to begin secondary-market purchases within 12 months and to accumulate at least 1 billion yuan in purchases within 18 months, with a non-transferable plan and an irrevocable donation if the target is not met, for FAST database and product development platform.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.